HK1095320A1 - Pyrimidine derivatives useful for the treatment of diseases mediated by crth2 - Google Patents

Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Info

Publication number
HK1095320A1
HK1095320A1 HK07100401.6A HK07100401A HK1095320A1 HK 1095320 A1 HK1095320 A1 HK 1095320A1 HK 07100401 A HK07100401 A HK 07100401A HK 1095320 A1 HK1095320 A1 HK 1095320A1
Authority
HK
Hong Kong
Prior art keywords
crth2
treatment
pyrimidine derivatives
diseases mediated
derivatives useful
Prior art date
Application number
HK07100401.6A
Other languages
English (en)
Inventor
Tai-Wei Ly
Yuji Koriyama
Takashi Yoshino
Hiroki Sato
Kazuho Tanaka
Hiromi Sugimoto
Yoshihisa Manabe
Kevin Bacon
Klaus Urbahns
Masanori Seki
Takuya Shintani
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of HK1095320A1 publication Critical patent/HK1095320A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07100401.6A 2003-04-25 2007-01-11 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2 HK1095320A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
PCT/EP2004/003910 WO2004096777A1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Publications (1)

Publication Number Publication Date
HK1095320A1 true HK1095320A1 (en) 2007-05-04

Family

ID=32946880

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100401.6A HK1095320A1 (en) 2003-04-25 2007-01-11 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Country Status (33)

Country Link
US (2) US7812160B2 (xx)
EP (2) EP1471057B1 (xx)
JP (2) JP4671955B2 (xx)
KR (1) KR101110491B1 (xx)
CN (2) CN101914065A (xx)
AR (1) AR043885A1 (xx)
AT (2) ATE316077T1 (xx)
AU (1) AU2004233966B2 (xx)
BR (1) BRPI0409733A (xx)
CA (1) CA2523439C (xx)
CL (1) CL43596B (xx)
CY (1) CY1111295T1 (xx)
DE (2) DE60303238T2 (xx)
DK (2) DK1471057T3 (xx)
DO (1) DOP2004000875A (xx)
ES (2) ES2257616T3 (xx)
GT (1) GT200400079A (xx)
HK (1) HK1095320A1 (xx)
HN (1) HN2004000129A (xx)
IL (1) IL171566A (xx)
MX (1) MXPA05011399A (xx)
MY (1) MY147984A (xx)
NO (1) NO20055588L (xx)
NZ (1) NZ543693A (xx)
PE (1) PE20050143A1 (xx)
PL (1) PL1633726T3 (xx)
PT (2) PT1471057E (xx)
RU (1) RU2361865C2 (xx)
SI (1) SI1633726T1 (xx)
TW (1) TWI353980B (xx)
UY (1) UY28286A1 (xx)
WO (1) WO2004096777A1 (xx)
ZA (1) ZA200508722B (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
ES2390344T3 (es) * 2003-12-23 2012-11-12 Genentech, Inc. Tratamiento de cáncer con anticuerpos monoclonales anti-IL13 novedosos
MXPA06007674A (es) * 2004-01-31 2006-09-04 Actimis Pharmaceuticals Inc Derivados del acido imidazo [1,2-c] pirimidinilacetico.
CN1930162B (zh) 2004-03-11 2010-06-16 埃科特莱茵药品有限公司 四氢吡啶并吲哚衍生物
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
AR051966A1 (es) 2004-11-23 2007-02-21 Astrazeneca Ab Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
MX2007012937A (es) 2005-04-21 2008-03-26 Serono Lab Pirazina-sulfonamidas 2,3-sustituidas.
CN101300259B (zh) 2005-05-24 2013-08-28 默克雪兰诺有限公司 作为crth2调节剂的三环螺衍生物
DOP2006000210A (es) * 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) * 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
CA2654784A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenylacetic acids as dp-2 antagonists
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
RU2468012C2 (ru) * 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Частицы антагониста crth2
RU2468013C2 (ru) * 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Аминовые соли антагониста crth2
UA100983C2 (xx) 2007-07-05 2013-02-25 Астразенека Аб Біфенілоксипропанова кислота як модулятор crth2 і інтермедіати$бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
NZ584351A (en) * 2007-09-25 2012-03-30 Actimis Pharmaceuticals Inc 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
ES2383249T3 (es) * 2007-09-25 2012-06-19 Actimis Pharmaceuticals, Inc. Alquiltiopirimidinas como antagonistas de CRTH2
EA018901B1 (ru) 2008-02-01 2013-11-29 ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
EP2245022A4 (en) 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US20110190227A1 (en) 2008-07-03 2011-08-04 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
JP5586606B2 (ja) * 2008-09-02 2014-09-10 アクチミス ファーマシューティカルズ インコーポレーテッド Crth2アンタゴニストとしての同位体富化されたピリミジン−5−イル酢酸誘導体
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
BRPI0923592A2 (pt) 2008-12-25 2016-01-26 Taisho Pharmaceutical Co Ltd composto
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AU2010212970A1 (en) 2009-02-12 2011-08-18 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
CA2768492A1 (en) 2009-07-31 2011-02-03 Panmira Pharmaceuticals, Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
SG178252A1 (en) 2009-08-05 2012-03-29 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
BR112012012384A2 (pt) * 2009-11-24 2016-03-22 Boehringer Ingelheim Int processo para preparar um polímero do sal de colina de [4,6-bi(dimetilamino--2-(4-{[4-(trifluorometil)-benzoil]amino}benzil)pirimidin-5-il}
EA201270653A1 (ru) 2010-01-06 2012-11-30 ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи Антагонист dpи его применение
SI2528901T1 (sl) 2010-01-27 2015-10-30 Boehringer Ingelheim International Gmbh Pirazolne spojine kot CRTH2 antagonisti
WO2011162274A1 (ja) 2010-06-23 2011-12-29 大正製薬株式会社 イソキノリン誘導体
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2598143A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
WO2012013567A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical composition for treatment of respiratory and inflammatory diseases
WO2012054691A2 (en) 2010-10-20 2012-04-26 Valspar Sourcing, Inc. Water-based coating system with improved adhesion to a wide range of coated and uncoated substrates including muffler grade stainless steel
US9132129B2 (en) 2010-11-15 2015-09-15 Katholieke Universiteit Leuven Antiviral compounds
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
SI2709988T1 (sl) 2011-05-16 2017-11-30 Actimis Pharmaceuticals, Inc. Postopek za pripravo (4,6-bis-dimetilamino-2- (4- (4- trifluorometilbenzoil-amino)benzil) primidin-5-il) ocetne kisline
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) * 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
MXPA02011376A (es) * 2000-05-22 2004-02-26 Leo Pharma As Benzofenonas como inhibidores de il-1beta y tnf-alfa.
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
CN100406007C (zh) 2002-12-20 2008-07-30 安姆根有限公司 哮喘和过敏性炎症调节剂
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
RU2468013C2 (ru) 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Аминовые соли антагониста crth2
RU2468012C2 (ru) 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Частицы антагониста crth2

Also Published As

Publication number Publication date
US7812160B2 (en) 2010-10-12
TWI353980B (en) 2011-12-11
SI1633726T1 (sl) 2011-04-29
DOP2004000875A (es) 2004-10-31
ATE494279T1 (de) 2011-01-15
RU2005136655A (ru) 2006-06-10
CN1809539B (zh) 2012-05-09
ZA200508722B (en) 2006-12-27
EP1633726A1 (en) 2006-03-15
MXPA05011399A (es) 2006-05-31
DK1633726T3 (da) 2011-03-28
US20070129355A1 (en) 2007-06-07
EP1633726B1 (en) 2011-01-05
PE20050143A1 (es) 2005-04-01
UY28286A1 (es) 2004-11-30
TW200505873A (en) 2005-02-16
MY147984A (en) 2013-02-28
CN101914065A (zh) 2010-12-15
IL171566A (en) 2011-03-31
ES2257616T3 (es) 2006-08-01
CA2523439A1 (en) 2004-11-11
EP1471057A1 (en) 2004-10-27
AU2004233966A1 (en) 2004-11-11
US20100322980A1 (en) 2010-12-23
US7960393B2 (en) 2011-06-14
AR043885A1 (es) 2005-08-17
CY1111295T1 (el) 2015-08-05
JP2006524645A (ja) 2006-11-02
JP2011068657A (ja) 2011-04-07
JP5161290B2 (ja) 2013-03-13
EP1471057B1 (en) 2006-01-18
PL1633726T3 (pl) 2011-06-30
KR20060089622A (ko) 2006-08-09
NO20055588L (no) 2006-01-24
DK1471057T3 (da) 2006-05-15
KR101110491B1 (ko) 2012-01-31
JP4671955B2 (ja) 2011-04-20
AU2004233966B2 (en) 2010-11-11
CN1809539A (zh) 2006-07-26
DE602004030907D1 (de) 2011-02-17
PT1633726E (pt) 2011-02-22
BRPI0409733A (pt) 2006-05-09
CL43596B (es) 2005-03-18
ES2358424T3 (es) 2011-05-10
RU2361865C2 (ru) 2009-07-20
ATE316077T1 (de) 2006-02-15
PT1471057E (pt) 2006-05-31
DE60303238D1 (de) 2006-04-06
CA2523439C (en) 2012-06-19
DE60303238T2 (de) 2006-09-14
HN2004000129A (es) 2009-05-14
GT200400079A (es) 2004-11-30
NO20055588D0 (no) 2005-11-25
WO2004096777A1 (en) 2004-11-11
NZ543693A (en) 2009-05-31

Similar Documents

Publication Publication Date Title
HK1095320A1 (en) Pyrimidine derivatives useful for the treatment of diseases mediated by crth2
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
AP2006003671A0 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
IL172346A0 (en) Treatment of t cell mediated diseases by inhibition of fgfr3
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
GB0329874D0 (en) Compounds useful for the treatment of diseases
SI1685125T1 (sl) Derivati pirola, primerni za zdravljenje proliferativnih bolezni
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL166226A0 (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders
IL172377A0 (en) 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders
GB0201025D0 (en) The treatment of degenerative diseases
ZA200606780B (en) Compounds for the treatment of diseases
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0312840D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312842D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0217205D0 (en) 2-Amino-pyridine derivatives useful for the treatment of diseases
GB0326967D0 (en) Use of pyrimidine derivatives for the treatment of psychiatric disorders
SI1534391T1 (sl) Novi piperazinil-pirazinonski derivati za zdravljenje motenj, povezanih z receptorjem 5-HT2A